A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
about
A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.Emerging immune targets for the treatment of multiple myeloma.Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall.ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes
P2860
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@ast
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@en
type
label
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@ast
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@en
prefLabel
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@ast
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@en
P2093
P2860
P1433
P1476
A single-arm, open-label, phas ...... th smoldering multiple myeloma
@en
P2093
Anna Teige Wickenberg
Björn Frendeus
Elisabeth Sonesson
Gunnar Juliusson
Ingrid Teige
Magnus Korsgren
Markus Hansson
Stina Wichert
Åsa Johansson
P2860
P304
P356
10.1371/JOURNAL.PONE.0171205
P407
P577
2017-02-03T00:00:00Z